Dr. Dave Lennon serves as the President and Chief Executive Officer of Whitehawk Therapeutics. In his executive capacity, he directs the clinical-stage oncology therapeutics enterprise's strategic initiatives, guiding the advancement of next-generation antibody-drug conjugates designed to target difficult-to-treat solid tumors, expand oncology pipelines, and manage corporate governance following the company's strategic evolution.